- About
- PsychU For You
- Topics
- Events
- Content
Patient Treatment Preferences in Bipolar-I Disorder: Are We Really Listening?
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Patient Treatment Preferences in Bipolar-I Disorder: Are We Really Listening?
Pharmacological treatment with oral or long acting injectable medications are recommended to reduce relapse risk and promote quality of life in patients with Bipolar-I Disorder. Healthcare providers and patients with Bipolar-I Disorder share many treatment goals, valuing treatment efficacy and stability and allowing patients to engage effectively within society and live life with a sense of normalcy. Addressing patient preferences in treatment planning and ensuring those align with treatment goals is essential in providing quality mental health care.
This on-demand webinar features Roger McIntyre, MD, FRCPC, and Kevin Williams, MS, MPAS, PA-C, who share their clinically-informed approaches to empower healthcare providers to engage in meaningful conversations with patients and translate patient preferences and goals into optimized treatment plans.
Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto, Head of the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada
MoreDr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada; Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada, Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois; Professor and Nanshan Scholar at Guangzhou Medical University; Adjunct Professor at College of Medicine in Korea University; and Clinical Professor at State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA, and at Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Kevin Williams, MS, MPAS, PA-C
CEO, Lead Clinician, OnPoint Behavioral Health Inc.
MoreKevin Williams, MS, MPAS, PA-C received a master’s degree in Interdisciplinary Medical Sciences from the University of South Florida and master’s degree in Physician Assistant Studies from South University. He is the CEO and Lead Clinician of OnPoint Behavioral Health Inc. in the Tampa Bay area where he provides innovative, holistic, and compassionate care to patients of all ages and has over 6 years of experience treating patients across inpatient, outpatient, and long-term care settings.Dr. Roger McIntyre, MD, FRCPC and Mr. Kevin Williams, MS, MPAS, PA-C are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
February 2023 US.CORP.X.24.00040Related Events
Registration
- PsychU For You
